ReNeuron Group (RENE) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 Sep 2024 07:00 AM
RNS
Cancellation - ReNeuron Group Plc
30 Aug 2024 07:00 AM
RNS
Corporate update and AIM cancellation
02 Aug 2024 12:25 PM
RNS
Corporate Update
26 Jun 2024 03:33 PM
RNS
Change of Registered Address
05 Jun 2024 03:36 PM
RNS
Creditor’s decision on Administrators' Proposals
17 May 2024 12:45 PM
RNS
Publication of Joint Administrators' Proposals
08 May 2024 07:00 AM
RNS
Update on Administration Process
17 Apr 2024 11:30 AM
RNS
Directorate Change
20 Mar 2024 03:43 PM
RNS
Appointment of Administrators
20 Mar 2024 12:30 PM
RNS
Intention to Appoint Administrators
01 Mar 2024 07:00 AM
RNS
Block Listing Review & Total Voting Rights
05 Feb 2024 02:30 PM
RNS
Corporate update and suspension of trading on AIM
05 Feb 2024 02:30 PM
RNS
Suspension - ReNeuron Group plc
27 Nov 2023 08:53 AM
EQS
Edison issues update on ReNeuron Group (RENE)...
08 Nov 2023 07:01 AM
RNS
Interim Results for the six months ended 30 Sept
08 Nov 2023 07:00 AM
RNS
ReNeuron presents in vivo data at Cell 2023
04 Sep 2023 07:00 AM
RNS
R&D Update
01 Sep 2023 07:00 AM
RNS
Block Listing Review & Total Voting Rights
29 Aug 2023 07:00 AM
RNS
Director declaration
22 Aug 2023 10:34 AM
RNS
Result of AGM
24 Jul 2023 05:20 PM
RNS
Notice of AGM
12 Jul 2023 11:57 AM
RNS
Share Purchase by Chief Financial Officer
16 Jun 2023 05:12 PM
RNS
Share Purchase by Senior Independent NED
16 Jun 2023 02:26 PM
RNS
Share Purchase by Executive Chairman
16 Jun 2023 07:00 AM
RNS
Posting of Annual Report & Accounts
05 Jun 2023 04:30 PM
RNS
Holding(s) in Company
25 May 2023 07:00 AM
RNS
Unaudited Preliminary Results
18 May 2023 07:00 AM
RNS
Notice of Results
17 May 2023 08:56 AM
RNS
Holding(s) in Company
27 Apr 2023 08:18 AM
RNS
Holding(s) in Company
06 Apr 2023 04:17 PM
RNS
Share Purchase by Senior Independent NED
03 Apr 2023 07:00 AM
RNS
New Scientific Advisory Board
28 Mar 2023 02:23 PM
RNS
Director/PDMR Shareholding
23 Mar 2023 07:00 AM
RNS
Change of adviser
13 Mar 2023 07:00 AM
RNS
ReNeuron to present at Advanced Therapies 2023
09 Mar 2023 04:03 PM
RNS
Holding(s) in Company
03 Mar 2023 09:37 AM
RNS
Share Purchase by Chief Financial Officer
01 Mar 2023 07:01 AM
RNS
Block listing application
01 Mar 2023 07:00 AM
RNS
Block Listing Review & Total Voting Rights
24 Feb 2023 11:20 AM
RNS
Director Share Purchases
15 Feb 2023 07:00 AM
RNS
Grant of Options
30 Jan 2023 04:38 PM
RNS
Director/PDMR Shareholding
27 Jan 2023 11:05 AM
RNS
Second Price Monitoring Extn
27 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
24 Jan 2023 10:55 AM
RNS
Share Purchase by Chief Financial Officer
23 Jan 2023 03:04 PM
RNS
Share Purchase by Executive Chairman
19 Jan 2023 07:00 AM
RNS
Company restructuring update
03 Jan 2023 07:02 AM
RNS
Total Voting Rights
03 Jan 2023 07:00 AM
RNS
Directorate Change
12 Dec 2022 02:31 PM
RNS
Holding(s) in Company

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

It listed on AIM in 2006 under the ticker RENE.

UK 100

Latest directors dealings